PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.79%
Cash & equivalents declining -13.79% while AXSM's grows 0.70%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-13.79%
Below half of AXSM's 0.70%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AXSM's 2.07%. David Dodd sees a leaner approach to short-term items.
-99.57%
Below half of AXSM's 8.49%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Below half of AXSM's 7.23%. Michael Burry sees a potential red flag for stagnation or capital shortage.
12.57%
Above 1.5x AXSM's 6.97%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.70%
Less than half of AXSM's 40.25%. David Dodd sees a more disciplined short-term liability approach.
-28.84%
Similar yoy to AXSM's -30.63%. Walter Schloss sees parallel approaches to long-term financing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.84%
1.1-1.25x AXSM's -25.02%. Bill Ackman questions if the firm is outpacing competitor in long-term leverage.
No Data
No Data available this quarter, please select a different quarter.
-22.64%
Less than half of AXSM's 4.28%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.84%
Similar yoy to AXSM's -4.06%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.67%
Below half AXSM's 37.35%. Michael Burry sees potential underperformance in building shareholder capital.
-99.57%
Below half AXSM's 7.23%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.84%
Less than half of AXSM's 2.81%. David Dodd sees less overall debt expansion vs. competitor.
-28.87%
Less than half of AXSM's 4.12%. David Dodd sees better deleveraging or stronger cash buildup than competitor.